Today, Cadila Pharmaceuticals announced the launch of its adalimumab biosimilar, Cadalimab™, in India. HUMIRA® (adalimumab) is approved to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis. Cadila’s press release noted that “[i]n an effort to strengthen their biosimilar product portfolio, Cadalimab™ is the fourth biosimilar launched in the last 2 months by Cadila Pharmaceuticals.” Cadila has launched 3 other biosimilars in India in the last 2 months, namely Bevaro™ (bevacizumab), Ritucad™ (rituximab) and NuPTH (teriparatide) for treatment of cancer and osteoporosis.
